Challenges in the Clinical Diagnosis of Ehlers Danlos Syndrome - A Multisystem Disorder By: Sittie Tula

Ehlers-Danlos syndrome (EDS) encompasses 13 inherited disorders which weaken parts of the human frame—specifically the body's connective tissues. The mutations interfere with how the body creates or structures collagen, which is a necessary protein for stretching and the strength of bones. (Zschocke, et.al., 2024) It has been observed that collagen exists as a central substance in the outer layer of the body, bone connections, and the tubes that carry blood. Mistakes happen during the creation of this protein; visible signs like bone connections that move too far, thin outer layers, and slow healing of injuries are often witnessed by patients. Various types of Ehlers-Danlos syndrome show different levels of pain or physical struggle, which causes identifying the illness to be a slow process for many individuals. The specific Ehlers-Danlos syndrome category is often identified late because the symptoms appear differently in every person.  (Aubry‐Rozier, et.al., 2021)

Hippocrates, who was a medical professional in ancient times, provided descriptions of Ehlers-Danlos syndrome at around 400 B.C (Parapia & Jackson, 2008). Ehlers-Danlos syndrome was not given formal recognition until the end of the 19th century and the commencement of the 20th century. Many people believe that the name of Ehlers-Danlos syndrome was fixed after dermatologists Edvard Ehlers and Henri-Alexandre Danlos provided their specific studies in 1901 and 1908. Ehlers-Danlos syndrome is estimated to exist in 1 in 5,000 individuals across the globe, while newer research suggests that Ehlers-Danlos syndrome affects 1 in 500 individuals. Within the borders of the United States, with an estimation that Ehlers-Danlos syndrome manifests between 1 in 2,500 and 1 in 5,000 individuals (Demmler, et al., 2019).

Experts claim that even though genetic testing has reached an elevated level, the diverse ways EDS subtypes appear in patients remain poorly understood. Studying rare diseases has great value for medical professionals and those in scientific investigations because rare diseases present unique difficulties. (Vandersteen, et al., 2023) Specific problems in medical identification and the creation of public health policy are caused by the low number of individuals who live with these conditions. Rare diseases require more attention because the small population of patients creates obstacles for those in a working position within the healthcare field. 

Study evidence indicates that an individual with EDS not only experiences chronic pain and fatigue, but multiple other serious health conditions which impact the individual's quality of life. Quality of care can involve making the person's voice heard in their own plan of care, along with a greater understanding of this condition. Strategies which lead to energy self-management, modifying daily life, and learning self-pacing help decrease symptom flares while protecting their preserved health. 

The paper addresses some of the rare diseases which do not feature enough in scientific studies. In this case, the rare connective tissue disease, Ehlers-Danlos syndrome (EDS). Because of Ehlers-Danlos syndrome, which has many types due to different genes involved, it should get much more coverage to give due regard to the millions affected worldwide. This paper aims to give it more prominence, making it more known and support campaigning to improve the level of treatment and diagnostics available. Ultimately, strengthening healthcare systems, promoting targeted research, and improving patient outcomes are essential steps toward supporting both individuals and communities impacted by EDS.

Background of the Study 

Initially characterized in the late 19th century, Ehlers-Danlos syndrome (EDS) is a heterogenous group of connective tissue diseases which continue to pique the attention of physicians and researchers. Extensive literature has documented the marked predisposition of patients with EDS to vascular complications as it has become well recognized that patients are likely to experience devastating complications of aneurysms and artery rupture. (Buso, etal., 2024)

The literature from contemporary sources emphasizes the value of multi-disciplinary management, and a newly published paper suggests individualized approaches (McAlpine, et.al., 2018). The combination of genetics, cardiology, and physical therapy specialists in an integrated team further emphasizes the disorder’s intricate nature and the importance of comprehensive patient care. 

Because Ehlers-Danlos Syndrome (EDS) manifests in many ways, physicians and other health professionals can have a challenging time in determining if patients are suffering from EDS versus other medical conditions. Physicians should always consider EDS in a comprehensive differential diagnosis and should use clinical findings, the history and presentation of the symptoms, and in some cases genetic testing to determine the correct type of EDS and the best course of treatment. 

We are seeing more medical awareness of the condition, and this trend is going in the right direction for the better. The diagnosis system of EDS, particularly of hypermobile EDS (hEDS) was improved with the use of the 2017 criteria which aim to distinguish hEDS from HSD (hypermobility spectrum disorders). (Castori, et.al., 2017)

Still, patients often struggle to achieve a correct EDS diagnosis due to lack of symptom clarity and the overlapping presentation of various diseases. These struggles point to a definite need for more medical training regarding this disease and an increase in EDS awareness overall. (Halverson, et.al., 2023)

The growing body of evidence has pointed towards better accuracy in diagnosis of EDS, and thus better outcomes for the patients, when using standardized tools and systematic screening for symptoms. A consistent approach in diagnosis - covering both the physical symptoms, as well as the subjective outcome reporting - has been crucial in providing a holistic approach for the multifaced symptoms of Ehlers-Danlos Syndrome. Best treatment modalities available so far include the use of some pharmacological agents, tramadol in managing the pain associated with hypermobile type of EDS. (Clark, et.al. 2023)

EDS management revolves around minimizing patient symptomology to decrease pain, increase functionality, and optimize the quality of life the patient currently has. Treatment options include but are not limited to pain management through prescribed medication, therapy including both occupational and physical therapy, compression apparel and all-encompassing interdisciplinary approaches to patient management. 

Clinical evidence shows the critical nature of personalization, especially the assessment of risks of procedures such as surgery and points to the necessity of encompassing not only the physical needs but the psychosocial needs of patients. Quality of life to those with Ehlers Danlos Syndrome: In addition to pain, EDS can negatively influence patients in areas beyond pain. It is common to see a substantial number of individuals who struggle with their physical condition due to their associated disability, as well as the social effects associated with an invisible illness. Anxiety and depression are common concerns among EDS patients, which are typically related to the long process of getting a diagnosis. 

Management of Ehlers-Danlos syndrome (EDS) typically calls for a collaborative effort focusing on pain relief, rehabilitative exercise and management of other conditions like mast cell activation syndrome or sexual health problems. Medical approaches also exist, such as physical therapy exercises that increase the integrity of the joint, reduce pain, and help with the body’s awareness of its position in space (proprioception) in support of stretching or flexibility work. Pain medications commonly used for pain don’t always work well for those with EDS, leading practitioners to explore more cutting-edge treatments like off-label medications or specific topic medications for central pain sensitization and the overactive nerves in EDS. (Colman, et.al., 2023)

Surgical procedures for people with Ehlers-Danlos syndrome (EDS) call for modifications like multiple levels of suture repair, alongside precise care and consideration in relation to how the joint lies when working on the surgery (Yonko, et.al., 2021). For people with EDS, comprehensive lifelong preventative treatment for joint integrity preservation, pain control, and avoidance of problems is imperative. Essential treatments can consist of specialized low-impact actual remedy, joint-stabilizing actions, activity regulation, as well as healthy living as well as nourishment practices to maintain a level of working as well as increase quality of life.

Statement of the problem

This research study's objective is to investigate the clinical variations and the diagnostic challenges involved in Ehlers-Danlos Syndrome; how genotype paired with phenotype variations affect individual results; the association in between genetic mutations besides how extreme signs in different kinds of Ehlers-Danlos Syndrome manifest.

To address these objectives, the study seeks to answer the following research questions:

1. What are the underlying genetic and molecular factors that cause variation in EDS subtypes?

2. How can diagnostic criteria be strengthened to address issues raised by the clinical workforce during the EDS identification process?

3. What is the overall impact of EDS on patient experience across a variety of levels including social, psychological, and physical factors?

4. How can increased awareness of diagnoses of Ehlers-Danlos Syndrome aid patients?

In the absence of an identified cause in the genes, a lack of a diagnosis for hypermobile Ehlers–Danlos syndrome (hEDS) continues to complicate clinical management. Clinical practice has become particularly complicated due to difficulties in establishing the diagnosis due to the use of criteria such as subjective joint laxity, without biomarkers—causing a misdiagnosis of a different connective tissue disorder or even to another subgroup of EDS and other disorders of the hypermobility spectrum or poorly separated within other diagnostic categories. (Tinkle, et.al., 2017)

The problem of diagnosis impacts the treatment, based mainly on a treatment directed to the symptoms (pain treatment, physical rehabilitation, modifications in lifestyle) rather than to a cause of treatment. Without defined diagnostic tools and outcome measures, the results for the patients’ treatments are fragmented and non-uniform. Due to this, there is a requirement to invest in research to provide a consistent pathway for diagnosis, with standardized metrics and a solid foundation of evidence for treatments.

Scope and Delimitations

This work is the research in Ehlers-Danlos syndrome from perspective of clinical diversity, diagnostical difficulties, and patients experience. It describes all 13 recognized types of Ehlers-Danlos syndrome, based on data from medical literature and documented case reports. The mechanisms of how different genetic mutations and abnormal connective tissues lead to variable symptoms, how these symptoms affect patients' lives. Early diagnosis and multi-disciplinary approaches are emphasized as key to the good outcome. To broaden understanding of rare connective-tissue disorders, expand the fund of general knowledge among clinicians — compiling gathered data from previous studies and evidence in my work.

There will not be any laboratory experimentations in this study. Cases which belong to extremely rare subtypes of EDS, which are poorly represented in the scientific literature, are not included in the research; neither does it contain any research with clinical trials in the testing of treatment methods of any sort. Research is done only on the basis of secondary source information, like scientific publications which have passed Peer Reviewed test, clinical case-reports of patients, and case studies from patient reports. Omission of Laboratory and/or clinical tests limits the investigation on clinical diagnostic aspects of the Ehlers-Danlos syndrome.

Data Gathered 

Ehlers-Danlos Syndrome (EDS) is a congenital, genetic condition characterized by defects in the body's ability to synthesize and use collagen due to mutations in affected genes. EDS can begin at any time between childhood and adolescence, depending on the specific subtype of the syndrome. About 70% of the body's ability to synthesize and use collagen due to mutations in affected genes. EDS can begin at any time between childhood and adolescence, depending on the specific subtype of the syndrome (Sulli, et.al.,2018). About 70% of cases of EDS are inherited from either one or both parents; the other cases are caused by spontaneous, de novo mutation and are not inherited. Unfortunately, EDS can be hard to recognize as symptoms range in severity and often resemble other health conditions or might be brushed aside as merely having "loose joints" or "growing pains." Additionally, because there are 13 different types of EDS, diagnosing the condition can prove to be challenging, especially when attempting to differentiate it from similar diseases and subtypes. (Hamel, 2019)

EDS is a set of disorders with two main forms—autosomal dominant and autosomal recessive that affects both males and females equally. Clinical findings, family history, and molecular genetic analysis are commonly used to make a diagnosis of this disorder, which has symptoms that can include hypermobile joints and thin, easily damaged skin as well as slow wound healing and chronic pain. Symptoms reflect the inability of collagen molecules to form normal, functional bonds and organize into stable mature chains. (Chiarelli, et.al.,2019)

The physical effects on the body include easier bruising, frequent dislocations, and when more extreme, potentially serious vascular problems like aneurysms or tearing of arteries (Westerman, et al., 2025). Within the autosomal dominant group, subtypes include Classic, Vascular, Arthrochalasia, Periodontal, and Hypermobile EDS. Types inherited with autosomal recessive patterns of inheritance include: Kyphoscoliotic, Classical-like, Cardiac-valvular, Dermatosparaxis, Musculocontractural, Spondylodysplastic and Brittle Cornea Syndrome. 

These diverse types collectively highlight the broad spectrum of clinical and genetic features characteristic of Ehlers-Danlos Syndrome and the need for an accurate diagnostic evaluation.

Average life expectancy is often considered normal in many EDS subtypes, particularly hypermobile or classical EDS. However, people with Vascular EDS (vEDS) often have a drastically decreased life expectancy of around 48-51 years due to extremely fragile arteries and other internal organs, (Pepin, et.al., 2000) a fatal concern during emergencies. Emergency treatment should be individualized to the subtype and must include timely CT/MRI, delicate-tissue surgical plans.

Ongoing EDS research is shifting away from symptom-focused care towards more molecular and regenerative strategies, with work in areas like blood proteomic screening that finds immune system and complement system markers for hypermobile EDS and cardiovascular drug use, including celiprolol and angiotensin receptor blockers (ARBs) (Dubacher, et.al. 2019) that show benefit in the prevention of arterial dissection in vascular EDS. New work is also illuminating the challenges EDS patients and doctors face, and research on EDS comorbidities, the pain mechanisms of EDS and the effectiveness of different treatments. Researchers are also looking into how the disease is influenced by genes and the variability in symptom manifestation to help tailor therapy in rehabilitation plans. Addressing all these questions can contribute to helping EDS patients better than before and will improve clinical practices and aid the system in addressing the need for comprehensive EDS care. 

Ehlers-Danlos syndrome (EDS) is typically characterized by repeated joint dislocations, chronic pain, a tendency for bruises to form, and slower healing rates-all these challenges often complicate diagnosis and treatment. Aids like canes, walkers, shower chairs, mattress toppers, and splints can make a big difference in day-to-day living by decreasing pressure on joints and improving stability. The impact of professional assistance is even more pronounced when mental health services go together with physiotherapy rather than being a substitute for it. (Mittal, et.al., 2021)

The ever-changing Ehlers-Danlos Syndromes are further elucidating the interweaving relationship between gene mutations, clinical manifestations, and psychosocial elements. While on the genetic front the continually expanding field of research continues to enhance our understanding of different EDS phenotypes and the associated impact that they carry with regard to clinical care, research into pain, psychosomatic manifestations and the comorbidity burden emphasizes the benefit of taking a mind-body perspective. The ability to detect it earlier, in tandem with interventions which facilitate care with both psychological and physical focus, may improve the quality of life experienced by patients (Petrucci, et.al. 2024). As there is not yet a unified treatment approach that takes the multiple nature of EDS into consideration, the future holds the promise of more studies in this area to enhance diagnosis and therapeutic options. 

By addressing the uncertainty surrounding diagnosis, and bringing the patients’ perspectives to light, this study improves clinical management and adds to advocacy for people with Ehlers-Danlos syndrome (EDS). It offers a better means of diagnosing, and more importantly a better understanding of the experience of those who have the disease. It highlights the need to blend innovation in science with a focus on patient experience to improve and educate about EDS.

References

Works Cited in MLA Format

Aubry‐Rozier, Bérengère et al... "Are patients with hypermobile Ehlers–Danlos syndrome or hypermobility spectrum disorder so different?" https://doi.org/10.1007/s00296-021-04968-3.pdf

Demmler, Joanne et al... "Diagnosed prevalence of Ehlers-Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case–control comparison."  https://bmjopen.bmj.com/content/bmjopen/9/11/e031365.full.pdf

Parapia, Liakat A. and Jackson, Carolyn. "Ehlers‐Danlos syndrome – a historical review." British Journal of Haematology, vol. 141, no. 1, 2008, pp. 32-35. https://doi.org/10.1111/j.1365-2141.2008.06994.x.

Vandersteen, Anthony M. et al. "Genetic complexity of diagnostically unresolved Ehlers-Danlos syndrome." https://jmg.bmj.com/content/jmedgenet/early/2023/10/09/jmg-2023-109329.full.pdf.

Zschocke, Johannes, Demirdas, Serwet, and Dijk, Fleur S. van. "Genetic diagnosis of the Ehlers-Danlos syndromes."  https://doi.org/10.1515/medgen-2024-2061/pdf. 

Buso, Giacomo et al... "Current Evidence and Future Perspectives in the Medical Management of Vascular Ehlers–Danlos Syndrome: Focus on Vascular Prevention."  https://www.mdpi.com/2077-0383/13/14/4255/pdf?version=1721549908.

Castori, Marco et al... "A framework for the classification of joint hypermobility and related conditions." American Journal of Medical Genetics Part C: Seminars in Medical Genetics, vol. 175, no. 1, 2017, pp. 148-157. https://doi.org/10.1002/ajmg.c.31539

Clark, Natalie et al... "Psychological interventions to improve pain, fatigue, anxiety, depression, and quality of life in children and adults with hypermobility spectrum disorders and Ehlers-Danlos syndrome: a systematic review."  https://doi.org/10.1007/s00296-023-05503-2.pdf

Colman, Marlies et al... "Sensory Profiling in Classical Ehlers-Danlos Syndrome: A Case-Control Study Revealing Pain Characteristics, Somatosensory Changes, and Impaired Pain Modulation."  http://www.jpain.org/article/S1526590023004509/pdf

Halverson, Colin et al... "Comorbidity, misdiagnoses, and the diagnostic odyssey in patients with hypermobile Ehlers-Danlos syndrome."  http://www.gimopen.org/article/S294977442300821X/pdf

McAlpine, James B. et al... "The value of universally available raw NMR data for transparency, reproducibility, and integrity in natural product research."  https://pubs.rsc.org/en/content/articlepdf/2019/np/c7np00064b.

Yonko, Elizabeth A. et al... "Orthopedic considerations and surgical outcomes in Ehlers–Danlos syndromes." American Journal of Medical Genetics Part C: Seminars in Medical Genetics, vol. 187, no. 4, 2021, pp. 458-465. https://doi.org/10.1002/ajmg.c.31958. 

Tinkle, Brad et al.. "Hypermobile Ehlers–Danlos syndrome (a.k.a. Ehlers–Danlos syndrome Type III and Ehlers–Danlos syndrome hypermobility type): Clinical description and natural history." American Journal of Medical Genetics Part C: Seminars in Medical Genetics, vol. 175, no. 1, 2017, pp. 48-69. https://doi.org/10.1002/ajmg.c.31538.

Chiarelli, Nicola et al.. "Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers‒Danlos Syndromes."  https://www.mdpi.com/2073-4425/10/8/609/pdf?version=1566195349.

Hamel, Ben C.J.. "Classification, nosology and diagnostics of Ehlers-Danlos syndrome."  https://ejournal2.undip.ac.id/index.php/jbtr/article/download/4531/3605.

Sulli, Alberto et al.. "Ehlers-Danlos syndromes: state of the art on clinical practice guidelines."  https://rmdopen.bmj.com/content/rmdopen/4/Suppl_1/e000790.full.pdf.

Westerman, Matt et al.. "Neurobiological and neuropsychological disturbance in EDS." https://doi.org/10.3389/fneur.2025.1648702/pdf.

Pepin, Melanie et al.. "Clinical and Genetic Features of Ehlers–Danlos Syndrome Type IV, the Vascular Type." New England Journal of Medicine, vol. 342, no. 10, 2000, pp. 673-680. https://doi.org/10.1056/NEJM200003093421001. 

Dubacher, Nicolo et al.. "Celiprolol but not losartan improves the biomechanical integrity of the aorta in a mouse model of vascular Ehlers–Danlos syndrome."  https://academic.oup.com/cardiovascres/article-pdf/116/2/457/31963310/cvz095.pdf.

Mittal, Nimish et al.. "The GoodHope Ehlers Danlos Syndrome Clinic: development and implementation of the first interdisciplinary program for multi-system issues in connective tissue disorders at the Toronto General Hospital." Orphanet Journal of Rare Diseases, vol. 16, no. 1, 2021. https://doi.org/10.1186/s13023-021-01962-7.

Petrucci, Taylor et al.. "Phenotypic Clusters and Multimorbidity in Hypermobile Ehlers-Danlos Syndrome."  https://www.mcpiqojournal.org/article/S2542-4548(24)00024-9/pdf.